Alchemab Therapeutics Names Kwon as Chief Financial and Operating Officer
16 November 2021 - - UK-based biotechnology company Alchemab Therapeutics has appointed Young T. Kwon, PhD as chief financial and operating officer, the company said.

Dr. Kwon brings over 20 years of experience in the biopharma and venture capital sectors. Most recently, he served as chief financial and Business officer of Momenta Pharmaceuticals, where he was responsible for business development, strategy, finance, investor relations, and commercial.

In that role, he led equity financings raising nearly USD 500m and led the company's sale to Johnson and Johnson for USD 6.5bn.

Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions.

Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies.

Dr. Kwon is a member of the board of directors of ADMA Biologics, a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.

He is also a scientific advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies. Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires.

The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.

Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.